These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 23916927)

  • 1. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study.
    Holmes MV; Simon T; Exeter HJ; Folkersen L; Asselbergs FW; Guardiola M; Cooper JA; Palmen J; Hubacek JA; Carruthers KF; Horne BD; Brunisholz KD; Mega JL; van Iperen EPA; Li M; Leusink M; Trompet S; Verschuren JJW; Hovingh GK; Dehghan A; Nelson CP; Kotti S; Danchin N; Scholz M; Haase CL; Rothenbacher D; Swerdlow DI; Kuchenbaecker KB; Staines-Urias E; Goel A; van 't Hooft F; Gertow K; de Faire U; Panayiotou AG; Tremoli E; Baldassarre D; Veglia F; Holdt LM; Beutner F; Gansevoort RT; Navis GJ; Mateo Leach I; Breitling LP; Brenner H; Thiery J; Dallmeier D; Franco-Cereceda A; Boer JMA; Stephens JW; Hofker MH; Tedgui A; Hofman A; Uitterlinden AG; Adamkova V; Pitha J; Onland-Moret NC; Cramer MJ; Nathoe HM; Spiering W; Klungel OH; Kumari M; Whincup PH; Morrow DA; Braund PS; Hall AS; Olsson AG; Doevendans PA; Trip MD; Tobin MD; Hamsten A; Watkins H; Koenig W; Nicolaides AN; Teupser D; Day INM; Carlquist JF; Gaunt TR; Ford I; Sattar N; Tsimikas S; Schwartz GG; Lawlor DA; Morris RW; Sandhu MS; Poledne R; Maitland-van der Zee AH; Khaw KT; Keating BJ; van der Harst P; Price JF; Mehta SR; Yusuf S; Witteman JCM; Franco OH; Jukema JW; de Knijff P; Tybjaerg-Hansen A; Rader DJ; Farrall M; Samani NJ; Kivimaki M; Fox KAA; Humphries SE; Anderson JL; Boekholdt SM; Palmer TM; Eriksson P; Paré G; Hingorani AD; Sabatine MS; Mallat Z; Casas JP; Talmud PJ
    J Am Coll Cardiol; 2013 Nov; 62(21):1966-1976. PubMed ID: 23916927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of PLA2G2A single nucleotide polymorphisms with type IIa secretory phospholipase A2 level but not its activity in patients with stable coronary heart disease.
    Shuvalova YA; Khasanova ZB; Kaminnaya VI; Samoilova EV; Korotaeva AA; Rubanovich AV; Kaminnyi AI
    Gene; 2015 Jun; 564(1):29-34. PubMed ID: 25794429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Group IIA Secretory Phospholipase A
    Akinkuolie AO; Lawler PR; Chu AY; Caulfield M; Mu J; Ding B; Nyberg F; Glynn RJ; Ridker PM; Hurt-Camejo E; Chasman DI; Mora S
    Arterioscler Thromb Vasc Biol; 2019 Jun; 39(6):1182-1190. PubMed ID: 31070471
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type II secretory phospholipase A2 and prognosis in patients with stable coronary heart disease: mendelian randomization study.
    Breitling LP; Koenig W; Fischer M; Mallat Z; Hengstenberg C; Rothenbacher D; Brenner H
    PLoS One; 2011; 6(7):e22318. PubMed ID: 21799821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease.
    Rosenson RS; Hurt-Camejo E
    J Am Coll Cardiol; 2014 Mar; 63(9):942-3. PubMed ID: 24315918
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply: limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease.
    Holmes MV; Simon T; Exeter HJ; Hingorani AD; Sabatine MS; Mallat Z; Casas JP; Talmud PJ
    J Am Coll Cardiol; 2014 Mar; 63(9):943. PubMed ID: 24315920
    [No Abstract]   [Full Text] [Related]  

  • 7. Novel genetic approach to investigate the role of plasma secretory phospholipase A2 (sPLA2)-V isoenzyme in coronary heart disease: modified Mendelian randomization analysis using PLA2G5 expression levels.
    Holmes MV; Exeter HJ; Folkersen L; Nelson CP; Guardiola M; Cooper JA; Sofat R; Boekholdt SM; Khaw KT; Li KW; Smith AJ; Van't Hooft F; Eriksson P; Franco-Cereceda A; Asselbergs FW; Boer JM; Onland-Moret NC; Hofker M; Erdmann J; Kivimaki M; Kumari M; Reiner AP; Keating BJ; Humphries SE; Hingorani AD; Mallat Z; Samani NJ; Talmud PJ;
    Circ Cardiovasc Genet; 2014 Apr; 7(2):144-50. PubMed ID: 24563418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Functional analysis of two PLA2G2A variants associated with secretory phospholipase A2-IIA levels.
    Exeter HJ; Folkersen L; Palmen J; Franco-Cereceda A; Cooper JA; Kalea AZ; Hooft FV; Eriksson P; Humphries SE; Talmud PJ
    PLoS One; 2012; 7(7):e41139. PubMed ID: 22879865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of varespladib methyl on biomarkers and major cardiovascular events in acute coronary syndrome patients.
    Rosenson RS; Hislop C; Elliott M; Stasiv Y; Goulder M; Waters D
    J Am Coll Cardiol; 2010 Sep; 56(14):1079-88. PubMed ID: 20863951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystatin C and Cardiovascular Disease: A Mendelian Randomization Study.
    van der Laan SW; Fall T; Soumaré A; Teumer A; Sedaghat S; Baumert J; Zabaneh D; van Setten J; Isgum I; Galesloot TE; Arpegård J; Amouyel P; Trompet S; Waldenberger M; Dörr M; Magnusson PK; Giedraitis V; Larsson A; Morris AP; Felix JF; Morrison AC; Franceschini N; Bis JC; Kavousi M; O'Donnell C; Drenos F; Tragante V; Munroe PB; Malik R; Dichgans M; Worrall BB; Erdmann J; Nelson CP; Samani NJ; Schunkert H; Marchini J; Patel RS; Hingorani AD; Lind L; Pedersen NL; de Graaf J; Kiemeney LA; Baumeister SE; Franco OH; Hofman A; Uitterlinden AG; Koenig W; Meisinger C; Peters A; Thorand B; Jukema JW; Eriksen BO; Toft I; Wilsgaard T; Onland-Moret NC; van der Schouw YT; Debette S; Kumari M; Svensson P; van der Harst P; Kivimaki M; Keating BJ; Sattar N; Dehghan A; Reiner AP; Ingelsson E; den Ruijter HM; de Bakker PI; Pasterkamp G; Ärnlöv J; Holmes MV; Asselbergs FW
    J Am Coll Cardiol; 2016 Aug; 68(9):934-45. PubMed ID: 27561768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tagging SNP haplotype analysis of the secretory PLA2-V gene, PLA2G5, shows strong association with LDL and oxLDL levels, suggesting functional distinction from sPLA2-IIA: results from the UDACS study.
    Wootton PT; Arora NL; Drenos F; Thompson SR; Cooper JA; Stephens JW; Hurel SJ; Hurt-Camejo E; Wiklund O; Humphries SE; Talmud PJ
    Hum Mol Genet; 2007 Jun; 16(12):1437-44. PubMed ID: 17545304
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
    JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phospholipase A2 group IIA correlates with circulating high-density lipoprotein cholesterol and modulates cholesterol efflux possibly through regulation of PPAR-γ/LXR-α/ABCA1 in macrophages.
    Liang L; Xie Q; Sun C; Wu Y; Zhang W; Li W
    J Transl Med; 2021 Nov; 19(1):484. PubMed ID: 34838043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS.
    De Luca D; Minucci A; Piastra M; Cogo PE; Vendittelli F; Marzano L; Gentile L; Giardina B; Conti G; Capoluongo ED
    PLoS One; 2012; 7(10):e47066. PubMed ID: 23071714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes.
    Mallat Z; Steg PG; Benessiano J; Tanguy ML; Fox KA; Collet JP; Dabbous OH; Henry P; Carruthers KF; Dauphin A; Arguelles CS; Masliah J; Hugel B; Montalescot G; Freyssinet JM; Asselain B; Tedgui A
    J Am Coll Cardiol; 2005 Oct; 46(7):1249-57. PubMed ID: 16198839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of Statins and Xuezhikang on the Expression of Secretory Phospholipase A2, Group IIA in Rat Vascular Smooth Muscle Cells.
    Xie Q; Zhang D
    Int Heart J; 2017 Feb; 58(1):115-124. PubMed ID: 28123160
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum secretory phospholipase A2-IIa (sPLA2-IIA) levels in patients surviving acute myocardial infarction.
    Xin H; Chen ZY; Lv XB; Liu S; Lian ZX; Cai SL
    Eur Rev Med Pharmacol Sci; 2013 Apr; 17(8):999-1004. PubMed ID: 23661511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statin therapy and secretory phospholipase A₂ in children with heterozygous familial hypercholesterolemia.
    Braamskamp MJ; Tsimikas S; Wiegman A; Kastelein JJ; Hutten BA
    Atherosclerosis; 2013 Aug; 229(2):404-7. PubMed ID: 23880195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciphering the Causal Role of sPLA2s and Lp-PLA2 in Coronary Heart Disease.
    Talmud PJ; Holmes MV
    Arterioscler Thromb Vasc Biol; 2015 Nov; 35(11):2281-9. PubMed ID: 26338298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.